SEARCH

SEARCH BY CITATION

References

  • 1
    Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002;13(Suppl. 1):S3740.
  • 2
    Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:258793.
  • 3
    Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med 2004;164:137388.
  • 4
    Renal U.S. Data System. USRDS 2006 Annual Data Report, Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases, 2006.
  • 5
    Jassal SV, Krishna G, Mallick NP, Mendelssohn DC. Attitudes of British Isles nephrologists towards dialysis modality selection: a questionnaire study. Nephrol Dial Transplant 2002;17:4747.
  • 6
    Korevaar JC, Feith GW, Dekker FW, et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64:22228.
  • 7
    Mehrotra R, Blake P, Berman N, Nolph KD. An analysis of dialysis training in the United States and Canada. Am J Kidney Dis 2002;40:15260.
  • 8
    Nissenson AR, Prichard SS, Cheng IK, et al. Non-medical factors that impact on ESRD modality selection. Kidney Int 1993;40(Suppl.):S1207.
  • 9
    Nissenson AR, Prichard SS, Cheng IK, et al. ESRD modality selection into the 21st century: the importance of non medical factors. ASAIO J 1997;43: 14350.
  • 10
    National Kidney Foundation. A-Z Health Guide. New York: National Kidney Foundation, 2006.
  • 11
    Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995;6:17783.
  • 12
    Collins AJ, Hao W, Xia H, et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999;34:106574.
  • 13
    Fenton SS, Schaubel DE, Desmeules M, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30: 33442.
  • 14
    Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003;14:41524.
  • 15
    Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002;17:1127.
  • 16
    Schaubel DE, Morrison HI, Fenton SS. Comparing mortality rates on CAPD/CCPD and hemodialysis. The Canadian experience: fact or fiction? Perit Dial Int 1998;18:47884.
  • 17
    Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003;64:10719.
  • 18
    Termorshuizen F, Korevaar JC, Dekker FW, et al. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:285160.
  • 19
    Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999;10:35465.
  • 20
    Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004;66:2389401.
  • 21
    Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comparing peritoneal dialysis and hemodialysis: what do they tell us? Kidney Int 2006;70 (Suppl.):S311.
  • 22
    Renal U.S. Data System. USRDS 2007 Annual Data Report, Atlas of End-Stage Renal Disease in the United States (Table I.20). Bethesda, MD: National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases, 2007.
  • 23
    Renal U.S. Data System. USRDS 2007 Annual Data Report, Atlas of End-Stage Renal Disease in the United States (Table I.27). Bethesda, MD: National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases, 2007.
  • 24
    Akpolat T, Dilek M, Yavuz M, et al. Low seroconversion rates in CAPD patients compared to hemodialysis patients: potential advantages for transplant candidates. Perit Dial Int 2002;22:5203.
  • 25
    Chavers BM, Solid CA, Gilbertson DT, Collins AJ. Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol 2007;18:9529.
  • 26
    Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in dialysis patients: the USRDS Wave 2 study. Kidney Int 2005; 68:3118.
  • 27
    Metcalfe W, Khan IH, Prescott GJ, et al. Hospitalization in the first year of renal replacement therapy for end-stage renal disease. Q J Med 2003;96:899909.
  • 28
    Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001;120:18837.
  • 29
    Renal U.S. Data System. USRDS 2007 Annual Data Report, Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes Digestive and Kidney Diseases, 2007.
  • 30
    Chandna SM, Farrington K. Residual renal function: considerations on its importance and preservation in dialysis patients. Semin Dial 2004;17:196201.
  • 31
    Divino Filho JC. Preservation of renal function: HDF versus PD. The paramount role of peritoneal dialysis. Blood Purif 2004;22(Suppl. 2):345.
  • 32
    Jansen MA, Hart AA, Korevaar JC, et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002;62:104653.
  • 33
    Lang SM, Bergner A, Topfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors. Perit Dial Int 2001;21:527.
  • 34
    Moist LM, Port FK, Orzol SM, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000;11:55664.
  • 35
    Radtke HW, Claussner A, Erbes PM, et al. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood 1979;54:87784.
  • 36
    Saxena R. Peritoneal dialysis: a viable renal replacement therapy option. Am J Med Sci 2005;330:3647.
  • 37
    Termorshuizen F, Korevaar JC, Dekker FW, et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003;41:1293302.
  • 38
    Misra M, Vonesh E, Van Stone JC, et al. Effect of cause and time of dropout on the residual GFR: a comparative analysis of the decline of GFR on dialysis. Kidney Int 2001;59:75463.
  • 39
    NKF-K/DOQI Clinical practice guidelines for peritoneal dialysis adequacy: update 2000. Am J Kidney Dis 2001;37(1 Suppl 1):S65136.
  • 40
    Lameire N, Peeters P, Vanholder R, Van Biesen W. Peritoneal dialysis in Europe: an analysis of its rise and fall. Blood Purif 2006;24:10714.
  • 41
    Blake P, Just P. Economics of dialysis. In: HorlWH, KochKM, LindsayRM, et al., eds. Replacement of Renal Function by Dialysis (5th ed.). Dordrecht: Kluwer Academic Publishers, 2004.
  • 42
    Covic AC, Goldsmith DJ, Florea L, et al. Should CAPD be the first choice for dialysis in Romania? Audit of the Iasi ‘C. I. Parhon’ Dialysis Center: 1995–2000. Nephrol Dial Transplant 2001;16:19962001.
  • 43
    Erek E, Sever MS, Akoglu E, et al. Cost of renal replacement therapy in Turkey. Nephrology (Carlton) 2004;9:338.
  • 44
    Lo WK. What factors contribute to differences in the practice of peritoneal dialysis between Asian countries and the West? Perit Dial Int 2002;22:24957.
  • 45
    Han F, Ye L, Qian J, et al. Social insurance cost of dialysis for patients with end stage renal disease in China. Presented at the World Congress of Nephrology. 2007, Rio de Janeiro, Brazil, pp. 179–80.
  • 46
    Hooi LS, Lim TO, Goh A, et al. Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia. Nephrology (Carlton) 2005;10:2532.
  • 47
    Li PK, Chow KM. The cost barrier to peritoneal dialysis in the developing world-an Asian perspective. Perit Dial Int 2001;21(Suppl. 3):S30713.
  • 48
    Prieto I, Bhattacharyya SK, Divino J, Paniagua R. Costs of treating ESRD patients with various dialysis therapies in Mexico. Presented at the 6th World Congress on Health Economics Copenhagen, Denmark, 2007.
  • 49
    Saffie A, Pacheco A, Tortella C, et al. Cost utility study in peritoneal diálysis (PD) and hemo diálysis (HD) in Chile. Presented at the 11th Congress of the International Society of Peritoneal Dialysis. Hong Kong, People's Republic of China, 2006.
  • 50
    Jung B, Blake PG, Mehta RL, Mendelssohn DC. Attitudes of Canadian nephrologists toward dialysis modality selection. Perit Dial Int 1999;19:2638.
  • 51
    Mendelssohn DC, Mullaney SR, Jung B, et al. What do American nephologists think about dialysis modality selection? Am J Kidney Dis 2001;37:229.
  • 52
    Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: a meta-analytic comparison. Am J Kidney Dis 2000;35:62937.
  • 53
    De Wit GA, Merkus MP, Krediet RT, De Charro FT. Health profiles and health preferences of dialysis patients. Nephrol Dial Transplant 2002;17:8692.
  • 54
    Harris SA, Lamping DL, Brown EA, Constantinovici N. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. Perit Dial Int 2002;22:46370.
  • 55
    Kutner NG, Zhang R, Barnhart H, Collins AJ. Health status and quality of life reported by incident patients after one year on haemodialysis or peritoneal dialysis. Nephrol Dial Transplant 2005;20:215967.
  • 56
    Manns B, Johnson JA, Taub K, et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants. Working Paper 02-05. National Library of Canada. August 2002.
  • 57
    Wu AW, Fink NE, Cagney KA, et al. Developing a health-related quality-of-life measure for end-stage renal disease: The CHOICE Health Experience Questionnaire. Am J Kidney Dis 2001;37:1121.
  • 58
    Wu AW, Fink NE, Marsh-Manzi JV, et al. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. J Am Soc Nephrol 2004;15:74353.
  • 59
    Barendse SM, Speight J, Bradley C. The Renal Treatment Satisfaction Questionnaire (RTSQ): a measure of satisfaction with treatment for chronic kidney failure. Am J Kidney Dis 2005;45:5729.
  • 60
    Rubin HR, Fink NE, Plantinga LC, et al. Patient ratings of dialysis care with peritoneal dialysis vs. hemodialysis. JAMA 2004;291:697703.
  • 61
    Golper T. Patient education: can it maximize the success of therapy? Nephrol Dial Transplant 2001; 16(Suppl. 7):204.
  • 62
    Gomez CG, Valido P, Celadilla O, et al. Validity of a standard information protocol provided to end-stage renal disease patients and its effect on treatment selection. Perit Dial Int 1999;19:4717.
  • 63
    Goovaerts T, Jadoul M, Goffin E. Influence of a pre-dialysis education programme (PDEP) on the mode of renal replacement therapy. Nephrol Dial Transplant 2005;20:18427.
  • 64
    Little J, Irwin A, Marshall T, et al. Predicting a patient's choice of dialysis modality: experience in a United Kingdom renal department. Am J Kidney Dis 2001;37:9816.
  • 65
    Marron B, Martinez Ocana JC, Salgueira M, et al. Analysis of patient flow into dialysis: role of education in choice of dialysis modality. Perit Dial Int 2005; 25(Suppl. 3):S569.
  • 66
    Prichard SS. Treatment modality selection in 150 consecutive patients starting ESRD therapy. Perit Dial Int 1996;16:6972.
  • 67
    Renal U.S. Data System. USRDS 2005 Annual Data Report, Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes Digestive and Kidney Disease, 2005.
  • 68
    Hirth RA. The organization and financing of kidney dialysis and transplant care in the United States of America. Int J Health Care Finance Econ 2007;7: 30118.
  • 69
    Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 2007; 10:33647.
  • 70
    Baboolal K, McEwan P, Sondhi S, et al. The cost of renal dialysis in a UK setting-a multicentre study. Nephrol Dial Transplant 2008;6:19829.
  • 71
    Chen L, Bhattacharyya S, Walker DR. The impact of higher PD utilization on Singapore's government expenditures. Accepted to the 3rd Asian Chapter Meeting of the International Society for Peritoneal Dialysis. Hiroshima, Japan, 2007.
  • 72
    Chowdhury S. Kidney dialysis. MOH Information Paper, 2006/013 2006, pp. 14.
  • 73
    Tan CC, Chan CM, Ho CK, et al. Health economics of renal replacement therapy: perspectives from Singapore. Kidney Int 2005;94(Suppl.):S1922.
  • 74
    Pacheco A, Saffie A, Torres R, et al. Cost/utility study of peritoneal dialysis and hemodialysis in Chile. Perit Dial Int 2007;27:35963.
  • 75
    Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007;10:6172.
  • 76
    Peeters P, Rublee D, Just PM, Joseph A. Analysis and interpretation of cost data in dialysis: review of Western European literature. Health Policy 2000;54: 20927.
  • 77
    Han F, Hu S, Qian J, et al. A research of payment on dialysis of ESRD patients with medical insurance. CMIA Research Report, 2006.
  • 78
    Sondhi S, Walker DR. In theUK, an increased utilization of peritoneal dialysis therapy could lead to an increase in the number of patients being treated for renal replacement therapy. Accepted for presentation at ISPOR 10th Annual European Congress. Dublin, Ireland, 2007.
  • 79
    Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32(Suppl.):S12041.
  • 80
    Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:10731.
  • 81
    Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:130720.
  • 82
    Walker DR, Bhattacharyya S, Prieto I, Paniagua R. Increased utilization of peritoneal dialysis therapy could substantially reduce dialysis budget for Mexico. Presented at the 8th European Peritoneal Dialysis Meeting. Helsinki, Finland, 2007.
  • 83
    Cusumano AM, Di Gioia C, Hermida O, Lavorato C. The Latin American dialysis and renal transplantation registry annual report 2002. Kidney Int Suppl 2005; 97(Suppl.):S4652.
  • 84
    Walker DR, Bhattacharyya S, Blackburn JC, et al. Substantial budget saving could be achieved by increasing utilization of peritoneal dialysis therapy in Chile. Presented at the 6th World Congress on Health Economics. Copenhagen, Denmark, 2007.
  • 85
    Walker DR, Bhattacharyya S, Capsa D. Reimbursement incentive for peritoneal dialysis may generate budget savings for Romania. Accepted for presentation at the ISPOR 10th Annual European Congress. Dublin, Ireland, 2007.
  • 86
    Sirivongs D. Asian peritoneal dialysis perspective. International Society for Peritoneal Dialysis (ISPD) Asian Chapter Newsletter 2006;4(1):2.
  • 87
    Li H, Hu S, Ye L, et al. Projected budget reduction from increased utilization of peritoneal dialysis in China. Presented at the World Congress of Nephrology. Rio de Janeiro, Brazil, 2007:184.
  • 88
    Sanabria M, Blackburn JC, Bhattacharyya S, et al. Hospitalization among dialysis patients in the renal therapy services (RTS) multi-centre network in Colombia. World Congress of Nephrology 2007 Book of Abstracts, 2007:198.
  • 89
    Gomez RA. Renal disease in Colombia. Ren Fail 2006;28:6437.
  • 90
    Walker DR, Sanabria M, Bhattacharyya S, et al. Impact of an incremental increase in peritoneal dialysis utilization on hospital budgets in Colombia: Use of a budget impact model. Value Health 2007;10: A1034.
  • 91
    Walker DR, Thaiyuenwong J, Bhattacharyya S, Chen L. Increased utilization of peritoneal dialysis therapy could substantially reduce the dialysis budget in Thailand. Accepted to the 3rd Asian Chapter Meeting of the International Society for Peritoneal Dialysis. Hiroshima, Japan, 2007.